Breaking Down Amylyx Pharma: 9 Analysts Share Their Views


Amylyx Pharma AMLX underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 6 0 3 0 0
Last 30D 1 0 0 0 0
1M Ago 1 0 1 0 0
2M Ago 3 0 2 0 0
3M Ago 1 0 0 0 0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.22, a high estimate of $32.00, and a low estimate of $3.00. Highlighting a 66.73% decrease, the current average has fallen from the previous average price target of $27.71.

Interpreting Analyst Ratings: A Closer Look

A comprehensive examination of how financial experts perceive Amylyx Pharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 -
Joel Beatty Baird Lowers Neutral $3.00 $4.00
Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 -
Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 $8.00
Andrew Fein HC Wainwright & Co. Lowers Buy $8.00 $42.00
Neena Bitritto-Garg Deutsche Bank Lowers Buy $8.00 $36.00
Chris Shibutani Goldman Sachs Lowers Neutral $4.00 $40.00
Joel Beatty Baird Lowers Neutral $4.00 $37.00
Graig Suvannavejh Mizuho Raises Buy $32.00 $27.00

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amylyx Pharma. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amylyx Pharma compared to the broader market.
  • Price Targets: Delving into movements, analysts provide estimates for the future value of Amylyx Pharma's stock. This analysis reveals shifts in analysts' expectations over time.

Capture valuable insights into Amylyx Pharma's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Amylyx Pharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Amylyx Pharma's Background

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Financial Insights: Amylyx Pharma

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Amylyx Pharma's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 395.54%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Amylyx Pharma's net margin excels beyond industry benchmarks, reaching 4.36%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Amylyx Pharma's ROE excels beyond industry benchmarks, reaching 1.11%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.96%, the company showcases effective utilization of assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.

Analyst Ratings: Simplified

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!